Andere talen Pharvaris N.V.

Aandelen

PHVS

NL00150005Y4

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
23,53 ^USD	-4,23%		+3,34%	-16,11%

15/04	PHARVARIS N.V. : Morgan Stanley herhaalt koopadvies	ZM
10/04	Pharvaris verkleint nettoverlies over Q4; neemt nieuwe CFO aan	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Pharvaris Files Mixed Shelf	12/04
Pharvaris Narrows Q4 Net Loss; Hires New CFO	10/04
Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	10/04
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	10/04
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer	10/04
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer	10/04
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference	04/04
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses	18/03
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses	18/03
Pharvaris N : Poster	15/03
Pharvaris N : EGM Meeting Minutes	12/03
Pharvaris N : Results of Extraordinary General Meeting of Shareholders - Form 6-K	06/03
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses	06/03
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses	06/03
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024	05/03
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024	05/03
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting	22/02
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting	22/02
Pharvaris Announces Extraordinary Meeting of Shareholders	16/02
Pharvaris Announces Extraordinary Meeting of Shareholders	16/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Pharvaris N.V.

Aandelen

PHVS

NL00150005Y4

Andere talen

Filters